Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites

NCT ID: NCT02436876

Last Updated: 2021-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-05-24
• Study Completion Date: 2018-07-26

Brief Summary

This study evaluates the safety and clinical benefit of MBN-101 administered intraoperatively to osteosynthesis or osteomyelitis sites for patients diagnosed with an orthopedic infection, with or without orthopaedic hardware. Three quarters of the patients will receive MBN-101, while the other one quarter will receive placebo.

Detailed Description

Postoperative orthopaedic infections, particularly antibiotic-resistant infections, present a serious clinical challenge to surgeons and other treating physicians. These infections frequently involve implanted foreign materials (stabilizing orthopaedic hardware), making infection of these sites much more likely than if foreign materials were not involved. MBN-101 has broad spectrum antimicrobial activity against orthopaedic wound pathogens.

This is a randomized, single-blind, placebo-controlled, multi-center study to assess the safety and tolerability of escalating doses of MBN-101 to treat orthopaedic infections during revision surgery, (a) with or without orthopaedic hardware, and (b) with or without removal and replacement of orthopaedic hardware.

Conditions

Bacterial Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Cohort 1

Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo

Group Type: EXPERIMENTAL

MBN-101

Intervention Type: DRUG

MBN-101 is a locally administered, anti-infective drug product

Placebo

Intervention Type: OTHER

The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Cohort 2

Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo

Group Type: EXPERIMENTAL

MBN-101

Intervention Type: DRUG

MBN-101 is a locally administered, anti-infective drug product

Placebo

Intervention Type: OTHER

The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Cohort 3

Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo

Group Type: EXPERIMENTAL

MBN-101

Intervention Type: DRUG

MBN-101 is a locally administered, anti-infective drug product

Placebo

Intervention Type: OTHER

The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Interventions

MBN-101

MBN-101 is a locally administered, anti-infective drug product

Intervention Type: DRUG

Placebo

The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient

Intervention Type: OTHER

Other Intervention Names

MBN-101 Drug Product; Diluent; Vehicle

Eligibility Criteria

Inclusion Criteria

• To be eligible for this study, each of the following criteria must be satisfied with a "YES" answer (unless not applicable):

Patients who:

• have had operative fracture fixation of the upper extremity (AO/OTA class 15, 11-13, 21-23), lower extremity (AO/OTA class 31-34, 41 44, 81, 82) or pelvis (61, 62), or have undergone arthrodesis, and have subsequently been diagnosed with an apparent fracture site infection or are diagnosed with chronic or acute-on-chronic osteomyelitis of the long bone extremities (including residual amputated limbs)
• have at least one of the following:
• require surgical debridement of infected soft tissue and/or bone, with or without removal and/or placement/replacement of hardware
• male or female between the ages of 18 and 75 at the time the ICF is reviewed and signed
• patients receiving or anticipated to receive systemic antibiotic therapy as per institution's standard of care
• patients requiring postoperative hospitalization for at least 48 hours after revision surgery
• have read and signed the Informed Consent Form (ICF) after the nature of the study has been fully explained
• be willing and able to provide authorization for use and disclosure of personal health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA)

Exclusion Criteria

• To be eligible for this study, each of the following criteria must be satisfied with a "NO" answer (unless not applicable):

• Patients who are no longer hardware dependent or are definitively treated for their infection by hardware removal without replacement
• Patients with multiple, non-contiguous sites of infection
• Pathologic fracture (not including osteoporosis)
• Patient requires immunosuppressive therapy (Topical or inhaled corticosteroids are permitted)
• Serum creatinine, ALT, AST or Alkaline Phosphatase >2.0 times the upper limit of the normal range of the local testing laboratory
• Absolute neutrophil count <1000
• Patients without definitive soft-tissue coverage over the surgical site at time of study product administration
• Any condition that has required treatment with any other bismuth containing compound within the last 2 weeks (i.e., Kaopectate or Pepto Bismol)
• Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months
• Individuals undergoing surgical treatment for more than one infected site
• Patients who are pregnant, lactating, or female patients who have a positive serum hCG (human Chorionic Gonadotropin) as determined by laboratory testing
• Immunocompromised due to illness or organ transplant
• History of chronic or recurrent infections (≥ 3 infections at the same site within 12 months)
• History of any type of cancer (excluding non-melanomatous localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix)
• Poorly controlled diabetes mellitus
• History of medical noncompliance
• Other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results.
• Current incarceration

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Pennsylvania

OTHER

Sponsor Role: collaborator

University of California, San Francisco

OTHER

Sponsor Role: collaborator

Medpace, Inc.

INDUSTRY

Sponsor Role: collaborator

Congressionally Directed Medical Research Programs

FED

Sponsor Role: collaborator

Microbion Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Brett Baker, MSc, DC

Role: STUDY_CHAIR

Microbion Corporation

Locations

Orthopedic Trauma Institute, University of California San Francisco

San Francisco, California, United States

UCSF - Parnassus

San Francisco, California, United States

LifeBridge Health, Inc.

Baltimore, Maryland, United States

OhioHealth Research Institute

Columbus, Ohio, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

The University of Texas - Health Science Center & Medical School at Houston

Houston, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

W81XWH-12-2-0100

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

MBN-101-201

Identifier Type: -

Identifier Source: org_study_id